Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers.

Literature DB >> 6318655

Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers.

P G Higgins, R J Phillpotts, G M Scott, J Wallace, L L Bernhardt, D A Tyrrell.

Abstract

In a double-blind, placebo-controlled study, self-administered intranasal human interferon alpha A produced by recombinant DNA technology was given both before and after virus challenge with a respiratory coronavirus. The incidence of colds, the severity of symptoms and signs, and virus replication were all reduced in subjects receiving interferon as compared with those given placebo.

Entities: Disease Gene Species

Mesh：

Substances：
Interferon Type I

Year: 1983 PMID： 6318655 PMCID： PMC185930 DOI： 10.1128/AAC.24.5.713

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

6 in total

1. Inhibition of respiratory virus infection by locally applied interferon.

Authors: T C Merigan; S E Reed; T S Hall; D A Tyrrell
Journal: Lancet Date: 1973-03-17 Impact factor: 79.321

2. Prevention of rhinovirus colds by human interferon alpha-2 from Escherichia coli.

Authors: G M Scott; R J Phillpotts; J Wallace; C L Gauci; J Greiner; D A Tyrrell
Journal: Lancet Date: 1982-07-24 Impact factor: 79.321

3. Purified interferon as protection against rhinovirus infection.

Authors: G M Scott; R J Phillpotts; J Wallace; D S Secher; K Cantell; D A Tyrrell
Journal: Br Med J (Clin Res Ed) Date: 1982-06-19

4. Clones of MRC-C cells may be superior to the parent line for the culture of 229E-like strains of human respiratory coronavirus.

Authors: R J Phillpotts
Journal: J Virol Methods Date: 1983-05 Impact factor: 2.014

5. An effective dosage regimen for prophylaxis against rhinovirus infection by intranasal administration of HuIFN-alpha 2.

Authors: R J Phillpotts; G M Scott; P G Higgins; J Wallace; D A Tyrrell; C L Gauci
Journal: Antiviral Res Date: 1983-08 Impact factor: 5.970

6. Failure of oral 4',6-dichloroflavan to protect against rhinovirus infection in man.

Authors: R J Phillpotts; J Wallace; D A Tyrrell; D S Freestone; W M Shepherd
Journal: Arch Virol Date: 1983 Impact factor: 2.574

6 in total

35 in total

1. Interfering with the real cold.

Authors: G Scott
Journal: Br Med J (Clin Res Ed) Date: 1986-05-31

2. Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infection.

Authors: K A Callow
Journal: J Hyg (Lond) Date: 1985-08

3. The time course of the immune response to experimental coronavirus infection of man.

Authors: K A Callow; H F Parry; M Sergeant; D A Tyrrell
Journal: Epidemiol Infect Date: 1990-10 Impact factor: 2.451

Review 4. Antiviral therapy. Respiratory infections, genital herpes, and herpetic keratitis.

Authors: K G Nicholson
Journal: Lancet Date: 1984-09-15 Impact factor: 79.321

5. Intranasally administered alpha/beta interferon prevents extension of mouse hepatitis virus, strain JHM, into the brains of BALB/cByJ mice.

Authors: A L Smith; S W Barthold; D S Beck
Journal: Antiviral Res Date: 1987-12 Impact factor: 5.970